施乐辉膝关节

施乐辉初次膝关节产品介绍,王建峰JohnnyWANG/膝关节产品经理,Headquarters-London,U.K.CEO-OlivierBouhon,Revenue-$4,100million(2013)Employees-11,000(2013),ThomasJamesSmith,Smith&NephewReconHeadquatersinMemphis/USA,1856年ThomasJamesSmith于英国Hull开设药局,1896年Smith的侄子HoratioNelsonSmith加入成为Smith&Nephew,1986年,收购了RichardsMedicalCompany，为医疗行业的引导者,IMSdata，2009,骨科领域主流公司发展状况,FutureKneeProcedures,*CAGRsbasedonbestestimatescenario,TrendsInTKR,TKRsInYoungerPatients-60%Males65-40%Females98%10-yrsurvivorship1Nooneelsehasanindustry-exclusive30yearwearclaimforLEGIONCRandPSbecausenooneelsehasVERILASTTechnology2VersatilitySeamlessoptionsfordiversesurgicalchallengesProvendesignsallownaturalanatomicreconstructionandofferpatient-appropriatematerialsEaseEasy,intuitiveinstrumentationOREfficienciesofVISIONAIREPatient-matchedTechnology+LEGIONCRPorousKnees,claim,TrademarkofSmith&Nephew.CertainmarksReg.USPat.&TMOff.,对比GII,XLPE-高交联垫片更少磨损股骨髁新设计-更宽泛适应症股骨工具独特设计-使用更加方便节省手术时间外旋截骨-更多假体类型适用更多术式-,-优良的髌骨轨迹-最大155高屈曲-解剖型胫骨托设计-相同的胫骨垫片设计,产品特点,外旋截骨器,Guideset2-6forLegion,Guideset0forGII,DrillholesforDCFblock,L,M,L,M,四合一截骨板,12mm,9.5mm,9.5mm,截骨后,假体植入后,9.5mm,9.5mm,7mm,LEGION的含义,“强大的古罗马军团；众多的”,LEGION可交换性,符合人体的解剖,假体几何结构J曲线，多中心半径设计符合大多数股骨部件的尺寸,符合人体的解剖,关节活动中髌骨滑动槽逐渐靠近中线,0,中线,60,90,外侧需要松解的几率：相比竞争对手的8-15%，LEGION只有3%,施乐辉是唯一一家公司提供不对称解剖型胫骨假体的公司,对称型胫骨平台过大,对称型胫骨平台过小,解剖型胫骨平台正好,符合人体的解剖,高屈曲设计,最大155高屈曲设计,TrademarkofSmith&Nephew.Reg.USPat.&TMOff.,LEGION股骨部件,LEGIONRevision&CR、PSOXINIUM及CoCr材料尺寸2-6号SPC设计APbox截骨相等,LEGIONCRLEGIONPSLEGIONRev,LEGION胫骨部件,GII&LEGION相同处材料=钛合金尺寸1-8号不对称设计相同锁定机制高抛光表面GII2.3mm厚度3后倾LEGION5.5mm厚度0后倾,GII（maletaper）,LEGION（Femaletaper）,LEGION胫骨衬垫,GII-CPE尺寸：1-8号厚度：Standard9,11,13,15,18mmPSHighFlex9,11,13,15,18,21,25mmConstrained11,13,15,18,21,25mmLEGION-XLPE尺寸：1-6号厚度：STD：HighFlex9,11,13and15mmConstrained：11,13,15,18mm,Basedonin-vitrowearsimulationtesting,theLEGIONPrimaryKneeSystemwithVERILASTtechnologyisexpectedtoprovidewearperformancesufficientfor30yearsofactualuseundertypicalconditions.Theresultsofin-vitrowearsimulationtestinghavenotbeenproventoquantitativelypredictclinicalwearperformance.Also,areductionintotalpolyethylenewearvolumeorwearratealonemaynotresultinanimprovedclinicaloutcomeaswearparticlesizeandmorphologyarealsocriticalfactorsintheevaluationofthepotentialforwearmediatedosteolysisandassociatedasepticimplantloosening.Particlesizeandmorphologywerenotevaluatedaspartofthetesting.TrademarkofSmith&Nephew.,VERILASTTechnologywithLEGIONPrimaryKneeSystem,Exclusive30yearwearperformance*claim,LEGIONTotalKneeSystemVERILASTTechnologythepowerofsimplicity,TrademarkofSmith&Nephew.Reg.USPat.&TMOff.,Legion/GenesisII系统人工全膝